positive
-
Spine
‘Floating’ plaque technique can provide additional spinal cord decompression
By Robert Linnehan Surgical techniques to treat thoracic ossification of the posterior longitudinal ligament vary in their outcomes, but evidence…
Read More » -
Recon
Ember Therapeutics Announce Initial Positive Results From a Phase 2 Trial of BMP-7 in Patients with Moderate Osteoarthritis of the Knee
NEW YORK, Oct. 19, 2015 /PRNewswire/ — Ember Therapeutics, Inc., a privately held, New York-based biopharmaceutical company that is developing targeted therapies for osteoarthritis,…
Read More » -
Spine
KUROS TO PRESENT POSITIVE KUR-115 PRE CLINICAL DATA FOR INTERBODY SPINAL FUSION TREATMENT AT THE 2015 NORTH AMERICAN SPINE SOCIETY
Zurich, Switzerland, 15th October 2015 – Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products, today announces…
Read More » -
Spine
VA Spinal Cord Injury Center Demonstrates Clinical Improvement With The EarlySense Monitoring System
WALTHAM, Massachusetts, September 8, 2015 /PRNewswire/ — A VA Spinal Cord Injury (SCI) Center has reported significant positive clinical results achieved with…
Read More » -
Biologics
CollPlant Reports Positive Interim Trial Results
CollPlant Ltd. (TASE:CLPT; OTC:CQPTY), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced…
Read More » -
Extremities
Anika Therapeutics Announces Positive Results from Follow-up Study Evaluating Safety of a Repeat Injection of CINGAL for Treatment of Osteoarthritis of the Knee
BEDFORD, Mass., Jul 09, 2015 (BUSINESS WIRE) — Anika Therapeutics, Inc., ANIK, +0.35% a leader in products for tissue protection, healing, and repair based…
Read More » -
BioMimetic Therapeutics’ Augment™ Bone Graft Receives Positive Recommendation from FDA Advisory Committee
Franklin, Tenn. – May 12, 2011 – BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), a biotechnology company specializing in the development and…
Read More »